Hologic price target raised to $78 from $76 at Evercore ISI

Evercore ISI raised the firm’s price target on Hologic to $78 from $76 and keeps an In Line rating on the shares. Hologic reported base organic growth of 5.5% ex-COVID, which came in at the high-end of its guidance range of 4%-5.6%, notes the analyst, who awaits the USPSTF guideline on pap testing update before giving credit for Hologic “slowly but steadily making case for being a consistent HSD-DD EPS grower.”